Twist Bioscience Company Insiders
| TWST Stock | USD 28.57 0.04 0.14% |
Twist Bioscience employs about 919 people. The company is managed by 27 executives with a total tenure of roughly 133 years, averaging almost 4.0 years of service per executive, having 34.04 employees per reported executive. Breaking down Twist Bioscience's management performance can provide insight into the firm performance.
| Emily Leproust CEO President CEO, Director |
| Patrick Weiss President Vice President - Operations |
Twist |
Twist Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.1587) % which means that it has lost $0.1587 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.308) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Twist Bioscience Workforce Comparison
Twist Bioscience Corp is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 377,227. Twist Bioscience adds roughly 919 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (0.78) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.66) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.66. Twist Bioscience Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Twist Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Twist Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Twist Bioscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adam Laponis over a week ago Disposition of 556 shares by Adam Laponis of Twist Bioscience at 33.155 subject to Rule 16b-3 | ||
Paula Green over two weeks ago Disposition of 229 shares by Paula Green of Twist Bioscience at 32.736 subject to Rule 16b-3 | ||
Dennis Cho over a month ago Disposition of tradable shares by Dennis Cho of Twist Bioscience at 34.6 subject to Rule 16b-3 | ||
William Banyai over a month ago Disposition of 549 shares by William Banyai of Twist Bioscience at 37.43 subject to Rule 16b-3 | ||
Werner Robert F over three months ago Acquisition by Werner Robert F of 5633 shares of Twist Bioscience subject to Rule 16b-3 | ||
Patrick Weiss over six months ago Exercise or conversion by Patrick Weiss of 827 shares of Twist Bioscience subject to Rule 16b-3 | ||
Werner Robert F over six months ago Twist Bioscience exotic insider transaction detected | ||
Kevin Yankton over six months ago Payment of tradable shares by Kevin Yankton of Twist Bioscience subject to Rule 16b-3 |
Twist Bioscience Notable Stakeholders
A Twist Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Twist Bioscience often face trade-offs trying to please all of them. Twist Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Twist Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Emily Leproust | President CEO, Director | Profile | |
| Patrick Weiss | Vice President - Operations | Profile | |
| Martin Kunz | Senior Vice President - Operation | Profile | |
| Mark Daniels | Senior Vice President Secretary, Chief Legal Officer, Chief Ethics and Compliance Officer | Profile | |
| Patrick Finn | Vice President of Sales and Marketing | Profile | |
| Paula Green | Vice President of Human Resources | Profile | |
| Bill Peck | CTO | Profile | |
| Paul Conley | Director | Profile | |
| Robert Ragusa | Director | Profile | |
| Jan Johannessen | Director | Profile | |
| Keith Crandell | Director | Profile | |
| Frederick Craves | Director | Profile | |
| Robert Chess | Lead Independent Director | Profile | |
| Mai Xiaoying | Director | Profile | |
| Nelson Chan | Director | Profile | |
| Xiaoying Mai | Independent Director | Profile | |
| Robert Werner | VP Officer | Profile | |
| Dennis Cho | General VP | Profile | |
| William Banyai | GM Development | Profile | |
| Aaron Sato | Chief Officer | Profile | |
| Erin Smith | Sr Policy | Profile | |
| Adam Laponis | Chief Officer | Profile | |
| Angela Bitting | Chief Affairs | Profile | |
| Kevin Yankton | VP Officer | Profile | |
| Chet Gandhi | Chief Officer | Profile | |
| Siyuan Chen | Chief Officer | Profile | |
| James Thorburn | Chief Officer | Profile |
About Twist Bioscience Management Performance
The success or failure of an entity such as Twist Bioscience Corp often depends on how effective the management is. Twist Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Twist management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Twist management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Twist Bioscience operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 989 people.
The data published in Twist Bioscience's official financial statements usually reflect Twist Bioscience's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Twist Bioscience Corp. For example, before you start analyzing numbers published by Twist accountants, it's critical to develop an understanding of what Twist Bioscience's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Twist Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Twist Bioscience's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Twist Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Twist Bioscience Corp. Please utilize our Beneish M Score to check the likelihood of Twist Bioscience's management manipulating its earnings.
Twist Bioscience Workforce Analysis
Traditionally, organizations such as Twist Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Twist Bioscience within its industry.Twist Bioscience Manpower Efficiency
Return on Twist Bioscience Manpower
| Revenue Per Employee | 266.7K | |
| Revenue Per Executive | 9.1M | |
| Net Loss Per Employee | 222.7K | |
| Net Loss Per Executive | 7.6M | |
| Working Capital Per Employee | 381.9K | |
| Working Capital Per Executive | 13M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Twist Bioscience Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Twist Stock analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is Twist Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Twist Bioscience. If investors know Twist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Twist Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Twist Bioscience Corp is measured differently than its book value, which is the value of Twist that is recorded on the company's balance sheet. Investors also form their own opinion of Twist Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Twist Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Twist Bioscience's market value can be influenced by many factors that don't directly affect Twist Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Twist Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Twist Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Twist Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.